论文部分内容阅读
目的为了观察铝碳酸镁与莫沙必利联合治疗功能性消化不良(FD)的临床疗效。方法采用随机对照研究,120例功能性消化不良患者,随机分为3组,A组40例,口服铝碳酸镁(商品名:威地镁)1000mg,每日3次;B组40例,口服莫沙必利(商品名:新络钠)5mg/次,每日3次;C组40例,口服铝碳酸镁1000mg,每日3次,莫沙必利5mg/次,每日3次。疗程均为4周。结果铝碳酸镁联合莫沙必利治疗组的有效率87.5%及显效率70.0%,明显优于单用铝碳酸镁及莫沙必利组治疗,有显著性差异(P<0.05),治疗后各组均未发现明显不良反应。结论铝碳酸镁与莫沙必利联合应用能有效缓解功能性消化不良(FD)的症状,疗效明显、安全可靠。
Objective To observe the clinical efficacy of combination of magnesium aluminum carbonate and mosapride in the treatment of functional dyspepsia (FD). Methods A randomized controlled study of 120 patients with functional dyspepsia was randomly divided into three groups: group A (n = 40), oral administration of magnesium aluminum carbonate (trade name: Viagra magnesium) 1000 mg three times a day; group B, 40 patients Mosapride (trade name: Xinluo sodium) 5mg / times 3 times a day; C group 40 cases, oral magnesium aluminum carbonate 1000mg, 3 times a day, mosapride 5mg / times, 3 times a day. The course of treatment is 4 weeks. Results The effective rate was 87.5% and the effective rate was 70.0% in the combination of magnesium carbonate and mosapride, which was significantly better than that of magnesium aluminum carbonate and mosapride alone (P <0.05). After treatment No obvious adverse reactions were found in all groups. Conclusion The combination of aluminum magnesium carbonate and mosapride can effectively relieve the symptoms of functional dyspepsia (FD), with obvious curative effect and safety.